141 related articles for article (PubMed ID: 36760158)
1. Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer.
Türkel A; Karaçin C; Öner İ; Şeyran E; Öksüzoğlu B
J Oncol Pharm Pract; 2023 Feb; ():10781552231156521. PubMed ID: 36760158
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review.
Sharaf B; AlMasri R; Abdel-Razeq N; Salama O; Hamad I; Abunasser M; Abdel-Razeq H
Clin Cosmet Investig Dermatol; 2022; 15():5-10. PubMed ID: 35023941
[TBL] [Abstract][Full Text] [Related]
3. Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation.
Anjaneyan G; Keechilat P; Duraisamy P; Eapen M
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35365472
[TBL] [Abstract][Full Text] [Related]
4. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
Sollena P; Nikolaou V; Soupos N; Kotteas E; Voudouri D; Stratigos AJ; Fattore D; Annunziata MC; Orlandi A; Di Nardo L; Apalla Z; Deilhes F; Romano MC; Fabbrocini G; Sibaud V; Peris K;
Breast Cancer Res Treat; 2021 Jan; 185(1):247-253. PubMed ID: 32914354
[TBL] [Abstract][Full Text] [Related]
5. Vortex keratopathy associated with ribociclib.
Türkel A; Özdoğan S; Yekedüz E; Şeyran E; Karaçin C; Ateş Ö
J Oncol Pharm Pract; 2023 Jan; 29(1):230-232. PubMed ID: 35570741
[TBL] [Abstract][Full Text] [Related]
6. Elevated transaminases and development of cardiomyopathy in a 32-year-old woman with metastatic breast cancer after treatment with ribociclib followed by palbociclib.
Watts C; Nadori K
J Oncol Pharm Pract; 2023 Jun; 29(4):962-966. PubMed ID: 36000297
[TBL] [Abstract][Full Text] [Related]
7. Ribociclib-induced visual hallucination in a patient with metastatic breast cancer.
Kapagan T; Bulut N; Demirer S; Erdem GU
J Oncol Pharm Pract; 2023 Sep; 29(6):1529-1532. PubMed ID: 37306182
[TBL] [Abstract][Full Text] [Related]
8. Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor.
Chan OB; Su JC; Yazdabadi A; Chan A
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e154-e156. PubMed ID: 34180575
[TBL] [Abstract][Full Text] [Related]
9. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).
Decker T; Lüdtke-Heckenkamp K; Melnichuk L; Hirmas N; Lübbe K; Zahn MO; Schmidt M; Denkert C; Lorenz R; Müller V; Zahm DM; Mundhenke C; Bauer S; Thill M; Seropian P; Filmann N; Loibl S
Breast; 2023 Dec; 72():103575. PubMed ID: 37690320
[TBL] [Abstract][Full Text] [Related]
10. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
11. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
12. Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review.
Gao S; Wei G; Hao Y
Pathol Oncol Res; 2023; 29():1611115. PubMed ID: 37483648
[TBL] [Abstract][Full Text] [Related]
13. Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study.
Rudlowski C; Beermann N; Leitzen L; Nuding B
Breast Care (Basel); 2020 Jun; 15(3):289-293. PubMed ID: 32774224
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
15. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
16. Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response.
Pasqualoni M; Orlandi A; Palazzo A; Garufi G; Cannizzaro MC; Pontolillo L; Pannunzio S; Cutigni C; Sollena P; Federico F; Bria E; Tortora G
Front Oncol; 2023; 13():1067264. PubMed ID: 36969030
[TBL] [Abstract][Full Text] [Related]
17. Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.
Edessa D; Sisay M
Breast Cancer (Dove Med Press); 2017; 9():567-579. PubMed ID: 29263697
[TBL] [Abstract][Full Text] [Related]
18. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
19. Ribociclib-induced pulmonary infiltrates in a patient with breast cancer.
Ünsal O; Özet A
J Oncol Pharm Pract; 2023 Sep; 29(6):1537-1540. PubMed ID: 37524106
[TBL] [Abstract][Full Text] [Related]
20. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]